BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19946262)

  • 1. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
    Kojima K; Konopleva M; Tsao T; Andreeff M; Ishida H; Shiotsu Y; Jin L; Tabe Y; Nakakuma H
    Leukemia; 2010 Jan; 24(1):33-43. PubMed ID: 19946262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
    Kojima K; McQueen T; Chen Y; Jacamo R; Konopleva M; Shinojima N; Shpall E; Huang X; Andreeff M
    Blood; 2011 Oct; 118(16):4431-9. PubMed ID: 21868571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
    Kojima K; Shimanuki M; Shikami M; Samudio IJ; Ruvolo V; Corn P; Hanaoka N; Konopleva M; Andreeff M; Nakakuma H
    Leukemia; 2008 Sep; 22(9):1728-36. PubMed ID: 18548093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 5. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
    Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
    Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
    Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
    Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
    Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
    Jin L; Tabe Y; Kojima K; Zhou Y; Pittaluga S; Konopleva M; Miida T; Raffeld M
    Cancer Lett; 2010 Dec; 299(2):161-70. PubMed ID: 20850924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
    Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress.
    Akiyama H; Umezawa Y; Ishida S; Okada K; Nogami A; Miura O
    Cancer Lett; 2019 Jul; 453():84-94. PubMed ID: 30946869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
    Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
    Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
    Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
    Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
    Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
    Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gö6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1.
    Yoshida A; Ookura M; Zokumasu K; Ueda T
    Biochem Pharmacol; 2014 Jul; 90(1):16-24. PubMed ID: 24735609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.